XSHG
688613
, Last price
Name
Allgens Medical Technology Co Ltd
Chart & performance
P/E
—
P/S
—
EPS
0.10
Vol. 1Y
—
Shs. 5Y
5.64%
Rev. 5Y
3.99%
Div Yld LY
—
Div Yld TTM
—
Revenues
224m
+8.48%
Net income
14m
P
CFO
39m
Dividend
Aug 06, 20260.0304 /sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Allgens Medical Technology Co. Ltd. operates as a medical device firm, concentrating on the development and production of sophisticated biomimetic synthetic bone graft systems. These innovative solutions are engineered for global deployment in areas where both cancellous (spongy) and cortical (dense outer layer) bone tissues have been compromised. The company's diverse product portfolio includes key offerings such as BonGold, a mineralized collagen scaffold designed for bone grafting procedures; the high-performance Alligator bone marrow aspirator; and OssaNova, a mineralized collagen-based material utilized for bone filling and augmentation. These products are broadly applied across a spectrum of orthopedic and skeletal repair interventions throughout the human anatomy. Allgens Medical Technology Co. Ltd. was established in 2004 and is headquartered in Beijing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||